The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The ERIC recommendations for Richter’s transformation: guidelines for management & trial design
Adam Kittai, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the importance of the recently published consensus guidelines for Richter’s transformation, stating that the ERIC recommendations aim to improve patient outcomes by unifying management practices and research. Dr Kittai highlights the need for better alignment across academia and private practices to ensure patients with Richter’s transformation receive the best care possible and emphasizes the value of designing clinical trials in a way that allows for inter-trial comparisons in the future. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Recently, we published a Richter’s Transformation Consortium Statement through ERIC guidelines in Blood Journal on the management, workup, and clinical trial recommendations for patients with Richter transformation. The reason why we decided to set off on this endeavor was that there were no guidelines or consensus statements available for Richter’s transformation, and we thought that by getting all of the experts into a room and coming up with key specific things that we want to state about the future and present of Richter transformation that hopefully we can make an impact on the survival for patients with Richter’s transformation moving forward...
Recently, we published a Richter’s Transformation Consortium Statement through ERIC guidelines in Blood Journal on the management, workup, and clinical trial recommendations for patients with Richter transformation. The reason why we decided to set off on this endeavor was that there were no guidelines or consensus statements available for Richter’s transformation, and we thought that by getting all of the experts into a room and coming up with key specific things that we want to state about the future and present of Richter transformation that hopefully we can make an impact on the survival for patients with Richter’s transformation moving forward.
So Richter’s transformation continues to be the unmet need of patients with CLL where the overall survival has been described as anywhere between six months to 24 months post-diagnosis and so we need to do better at aligning our research to make sure that we can identify new targets of intervention and also identify what we’re currently doing that works so that way we can use that intervention broadly amongst patients with Richter transformation. So we’re hopeful now that we have these consensus statements published that we will have more alignment across academia and also private practices in order to make sure that our patients with Richter transformation receive the best care moving forward.
Now one of the more interesting aspects of these specific consensus guidelines is the clinical trial recommendations. So I advise anybody who’s thinking about creating a clinical trial for patients with Richter’s transformation to take a look at that section closely and try to align what you’re doing in the clinical trial with what we suggest. So that way in the future when we have multiple clinical trials hopefully for patients with Richter’s we are better able to do cross-trial comparisons and we’re also all aiming to improve survival for patients with Richter’s transformation and designing trials that are specifically able to do that and also designing trials where we’re obtaining prospective biobanked samples in order to do better research in the future to help identify further weaknesses in the Richter transformation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
